# ALDX catalysts: Aldeyra Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/aldx/catalysts

> Aldeyra Therapeutics, Inc. (ALDX) has 2 upcoming catalysts. The next is the icm adx-2191 injection primary completion, December 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, year only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Aldeyra Therapeutics, Inc. |
| Ticker | ALDX (Nasdaq) |
| SEC CIK | 1341235 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/aldx |

## Cash runway

Cash $70.0M as of 2025-12-31; quarterly burn $5.3M; about 39.7 months of runway at that rate (XBRL company facts, accession 0001193125-26-083012).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Nov 2022 | [Reproxalap NDA/BLA submission](https://sec-api.dev/pdufa/reproxalap) | ALDX |  | completed | "Among other clinical trials of reproxalap, Aldeyra previously conducted two trials for ocular redness (a dry eye disease sign) in a dry eye chamber, and two dry eye disease symptom field (environmental exposure) trials, which were submitted as part of an initial NDA in November 2022." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/d946200dex992.htm)) |
| Dec 2022 | [Methotrexate Preservative Free (methotrexate) NDA/BLA acceptance](https://sec-api.dev/pdufa/methotrexate) | ALDX |  | completed | "Based on a pre-New Drug Application (NDA) meeting with the FDA in December 2022, Aldeyra submitted a literature-based NDA of ADX-2191 for the treatment of PVRL, which was accepted for Priority Review in March 2023." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1341235/000121390025058035/ea024700001ex99-1_aldeyra.htm)) |
| Jun 2023 | [Methotrexate Preservative Free (methotrexate) complete response letter (CRL)](https://sec-api.dev/pdufa/methotrexate) | ALDX | primary vitreoretinal lymphoma | completed, complete response letter | "In June 2023, we received a Complete Response Letter for our New Drug Application ("NDA") for ADX-2191 for the treatment of primary vitreoretinal lymphoma ("PVRL"), which stated that there was a lack of substantial evidence of effectiveness due to a lack of adequate and well-controlled investigations." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312526453537/aldx-20261109.htm)) |
| Nov 2023 | [Aldeyra Therapeutics, Inc. complete response letter (CRL)](https://sec-api.dev/companies/aldx/catalysts) | ALDX |  | completed, complete response letter | "In November 2023, the FDA issued a Complete Response Letter to the initial NDA stating that at least one additional symptom trial was required." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/d946200dex992.htm)) |
| November 23, 2023 | [Reproxalap PDUFA date](https://sec-api.dev/pdufa/reproxalap) | ALDX |  | completed, complete response letter | "In February 2023, the FDA accepted the Reproxalap NDA for filing and set a PDUFA date of November 23, 2023." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1341235/000095017025071602/aldx-20250331.htm)) |
| November 27, 2023 | [Reproxalap complete response letter (CRL)](https://sec-api.dev/pdufa/reproxalap) | ALDX | signs and symptoms of dry eye disease in December 2022 | completed, complete response letter | "We submitted an NDA (the Reproxalap NDA) for reproxalap for the treatment of the signs and symptoms of dry eye disease in December 2022 and on November 27, 2023, we announced that we had received a Complete Response Letter from the FDA regarding this filing (the 2023 Complete Response Letter)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1341235/000119312526449742/aldx-20260930.htm)) |
| November 27, 2023 | [Reproxalap NDA/BLA submission](https://sec-api.dev/pdufa/reproxalap) | ALDX | signs and symptoms of dry eye disease in December 2022 | completed | "We submitted an NDA (the Reproxalap NDA) for reproxalap for the treatment of the signs and symptoms of dry eye disease in December 2022 and on November 27, 2023, we announced that we had received a Complete Response Letter from the FDA regarding this filing (the 2023 Complete Response Letter)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1341235/000119312526449742/aldx-20260930.htm)) |
| Oct 2024 | [Reproxalap NDA/BLA submission](https://sec-api.dev/pdufa/reproxalap) | ALDX | signs and symptoms of dry eye disease in October 2024 | completed | "Aldeyra resubmitted an NDA (the "reproxalap NDA") for reproxalap for the treatment of the signs and symptoms of dry eye disease in October 2024." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm)) |
| Oct 2024 | [Reproxalap complete response letter (CRL)](https://sec-api.dev/pdufa/reproxalap) | ALDX |  | completed, complete response letter | "In October 2024, we resubmitted the Reproxalap NDA, which included results from a revised chamber trial in response to the 2023 Complete Response Letter and on April 3, 2025, we announced that we had received a Complete Response Letter from the FDA (2025 Complete Response Letter, and collectively with the 2023 Complete Response Letter, the Complete Response Letters) with respect to the resubmission." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1341235/000119312526449742/aldx-20260930.htm)) |
| November 15, 2024 | [Reproxalap NDA/BLA acceptance](https://sec-api.dev/pdufa/reproxalap) | ALDX | signs and symptoms of dry eye disease | completed | "Release") to announce the Extension Letter and that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's resubmitted New Drug Application (NDA) for reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease, and has assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000121390024099333/ea0221568-8k_aldeyra.htm)) |
| November 18, 2024 | [Aldeyra Therapeutics, Inc. NDA/BLA acceptance](https://sec-api.dev/companies/aldx/catalysts) | ALDX |  | completed | "On November 18, 2024, we announced that the FDA had accepted for review the Resubmitted NDA and assigned a PDUFA date of April 2, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1341235/000095017025071602/aldx-20250331.htm)) |
| 2025 | [ADX-629 topline data readout](https://sec-api.dev/pdufa/adx-629) | ALDX |  | scheduled | "Moderate Alcohol-Associated Hepatitis (ADX-629) ‡ Open-label Phase 2 clinical trial top-line results expected in 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/d946200dex991.htm)) |
| Q2 2025 | [Reproxalap topline data readout](https://sec-api.dev/pdufa/reproxalap) | ALDX |  | scheduled | "Top-line results from dry eye disease field and chamber clinical trials are expected in Q2 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/d946200dex991.htm)) |
| Apr 2025 | [Aldeyra Therapeutics, Inc. complete response letter (CRL)](https://sec-api.dev/companies/aldx/catalysts) | ALDX |  | completed, complete response letter | "In April 2025, Aldeyra received a Complete Response Letter from the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1341235/000121390025054949/ea0245870ex99-1_aldeyra.htm)) |
| mid-2025 | [Reproxalap NDA/BLA submission](https://sec-api.dev/pdufa/reproxalap) | ALDX |  | scheduled | "Pending the Type A meeting with the FDA, NDA resubmission is anticipated in mid-2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1341235/000119312525113275/d941544dex991.htm)) |
| April 2, 2025 | [Aldeyra Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/aldx/catalysts) | ALDX |  | delayed | "On November 18, 2024, we announced that the FDA had accepted for review the Resubmitted NDA and assigned a PDUFA date of April 2, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1341235/000095017025071602/aldx-20250331.htm)) |
| April 2, 2025 | [Reproxalap PDUFA date](https://sec-api.dev/pdufa/reproxalap) | ALDX | signs and symptoms of dry eye disease | completed, complete response letter | "Release") to announce the Extension Letter and that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's resubmitted New Drug Application (NDA) for reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease, and has assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000121390024099333/ea0221568-8k_aldeyra.htm)) |
| April 2, 2025 | [Reproxalap complete response letter (CRL)](https://sec-api.dev/pdufa/reproxalap) | ALDX | dry eye disease | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA216442_20250402.pdf%22)) |
| April 3, 2025 | [Reproxalap NDA/BLA submission](https://sec-api.dev/pdufa/reproxalap) | ALDX | dry eye disease | completed | "On April 3, 2025, Aldeyra issued the Press Release to announce that it had received a Complete Response Letter ("2025 Complete Response Letter") from the U.S. Food & Drug Administration ("FDA") regarding the Company's resubmitted New Drug Application ("resubmitted NDA") for reproxalap, an investigational drug candidate, for the treatment of dry eye disease." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/d946200d8k.htm)) |
| Jun 2025 | [Reproxalap NDA/BLA submission](https://sec-api.dev/pdufa/reproxalap) | ALDX |  | completed | "In June 2025, Aldeyra resubmitted the reproxalap NDA, which, based on written agreement with the FDA, primarily consisted of results from the additional dry eye chamber trial." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm)) |
| June 16, 2025 | [Aldeyra Therapeutics, Inc. NDA/BLA acceptance](https://sec-api.dev/companies/aldx/catalysts) | ALDX |  | completed | "Following submission on June 16, 2025, the NDA was accepted for review as a "complete class 2 response" by the FDA on July 16, 2025, with a target PDUFA action date of December 16, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1341235/000119312525319638/aldx-ex99_1.htm)) |
| June 18, 2025 | [ADX-629 primary completion](https://sec-api.dev/pdufa/adx-629) | ALDX | Alcohol Hepatitis | completed | "NCT06685692 (A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-18 (ACTUAL); Lead Sponsor Aldeyra Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06685692)) |
| July 17, 2025 | [Reproxalap NDA/BLA acceptance](https://sec-api.dev/pdufa/reproxalap) | ALDX | signs and symptoms of dry eye disease | completed | "On July 17, 2025, Aldeyra announced that the FDA accepted the reproxalap NDA for review and assigned a PDUFA date of December 16, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm)) |
| August 21, 2025 | [Aldeyra Therapeutics, Inc. NDA/BLA submission](https://sec-api.dev/companies/aldx/catalysts) | ALDX |  | completed | "Per the FDA's earlier request during the NDA review, the safety data from the field trial was submitted to the NDA on August 21, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1341235/000119312525319638/aldx-ex99_1.htm)) |
| December 15, 2025 | [Reproxalap PDUFA date](https://sec-api.dev/pdufa/reproxalap) | ALDX | signs and symptoms of dry eye disease | delayed | "On December 15, 2025, Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") issued a press release (the "Press Release") to announce that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act ("PDUFA") date for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312525319638/aldx-20251215.htm)) |
| December 16, 2025 | [Reproxalap PDUFA date](https://sec-api.dev/pdufa/reproxalap) | ALDX | signs and symptoms of dry eye disease | scheduled | "On July 17, 2025, Aldeyra announced that the FDA accepted the reproxalap NDA for review and assigned a PDUFA date of December 16, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm)) |
| 1H 2026 | [Methotrexate Preservative Free (methotrexate) trial start](https://sec-api.dev/pdufa/methotrexate) | ALDX |  | scheduled | "Based on feedback from the FDA, we plan to initiate a Phase 2/3 clinical trial of ADX-2191 in retinitis pigmentosa in the first half of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312526083012/aldx-20251231.htm)) |
| 2026 | [Methotrexate Preservative Free (methotrexate) topline data readout](https://sec-api.dev/pdufa/methotrexate) | ALDX |  | scheduled | "Top-line results from the clinical trial are expected in 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312526083012/aldx-20251231.htm)) |
| March 16, 2026 | [Reproxalap PDUFA date](https://sec-api.dev/pdufa/reproxalap) | ALDX |  | completed, complete response letter | "On December 15, 2025, Aldeyra announced that the FDA had requested submission of the clinical study report for the field trial, triggering an extension of the PDUFA date to March 16, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm)) |
| March 16, 2026 | [Aldeyra Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/aldx/catalysts) | ALDX |  | scheduled | "The extended PDUFA target action date is March 16, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1341235/000119312525319638/aldx-ex99_1.htm)) |
| March 16, 2026 | [Reproxalap complete response letter (CRL)](https://sec-api.dev/pdufa/reproxalap) | ALDX | dry eye disease | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA216442_20260316.pdf%22)) |
| May 1, 2026 | [Reproxalap NDA/BLA submission](https://sec-api.dev/pdufa/reproxalap) | ALDX | dry eye disease and | completed | "On May 1, 2026, Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") released an updated corporate overview presentation (the "Corporate Overview") which, among other things, disclosed (i) standardized treatment estimates and confidence intervals for the primary endpoints of all proposed commercial dosing regimen efficacy clinical trials of reproxalap submitted to the New Drug Application for the treatment of dry eye disease and (ii) Aldeyra's abbreviated interpretations of the U.S. Food & Drug Administration positions on the primary endpoints for the reproxalap clinical trials, as well as the Aldeyra positions on the primary endpoints." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312526199157/aldx-20260501.htm)) |
| September 29, 2026 | [Reproxalap complete response letter (CRL)](https://sec-api.dev/pdufa/reproxalap) | ALDX | dry eye disease | completed, complete response letter | "Based on the Type D meeting, on September 29, 2026, Aldeyra issued a press release (the Press Release) announcing the intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA's Office of New Drugs (OND), appealing the March 16, 2026 Complete Response Letter that denied approval of a New Drug Application for reproxalap for the treatment of dry eye disease, and the extension of Aldeyra's projected operational cash runway into 2029." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312526405954/aldx-20260929.htm)) |
| December 2029 | [Icm adx-2191 injection primary completion](https://sec-api.dev/pdufa/icm-adx-2191) | ALDX | Primary Vitreoretinal Lymphoma | scheduled | "NCT07402876 (A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Aldeyra Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07402876)) |
| Dec 2029 to Mar 2030 | [Icm adx-2191 injection topline data readout](https://sec-api.dev/pdufa/icm-adx-2191) | ALDX | Primary Vitreoretinal Lymphoma | scheduled | "NCT07402876 (A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Aldeyra Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07402876)) |

## Drugs

- [ADX-629](https://sec-api.dev/pdufa/adx-629): Alcohol Hepatitis
- [Icm adx-2191 injection](https://sec-api.dev/pdufa/icm-adx-2191): Primary Vitreoretinal Lymphoma
- [Reproxalap](https://sec-api.dev/pdufa/reproxalap): signs and symptoms of dry eye disease in december 2022, dry eye disease, signs and symptoms of dry eye disease, signs and symptoms of dry eye disease in october 2024, immune-mediated diseases, today, dry eye disease and

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/aldx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ALDX catalysts: Aldeyra Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/aldx/catalysts

```bibtex
@misc{secapidev_companies_aldx_catalysts_20261116,
  title        = {ALDX catalysts: Aldeyra Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/aldx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_aldx_catalysts_20261116","title":"ALDX catalysts: Aldeyra Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/aldx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
